ARTICLE
5 January 2022

Upcoming Information Session On Proposed Framework For Potential Pan-Canadian Formulary

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health at the request of Health Canada.
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On January 18, 2022, the Pan-Canadian Formulary Advisory Panel will be presenting an information session with their recommendations for the development of a framework for a potential pan-Canadian prescription drug list, or formulary.

The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health (CADTH) at the request of Health Canada. The information session will focus on the principles for developing a pan-Canadian formulary framework, a sample list of prescribed drugs to include on the potential formulary as a test case, and criteria and processes for expanding the sample list. Registration is free.  

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More